Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

References

• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Doxsey S, Zimmerman W, Mikule K. Centrosome control of the cell cycle. Trends Cell Biol 2005; 15: 303–311
   PubMed Web of Science ®Google Scholar
• Lacey K R, Jackson P K, Stearns T. Cyclin-dependent kinase control of centrosome duplication. Proc Natl Acad Sci USA 1999; 96: 2817–2822
   PubMed Web of Science ®Google Scholar
• Gromley A, Jurczyk A, Sillibourne J, Halilovic E, Mogensen M, Groisman I, et al. A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase. J Cell Biol 2003; 161: 535–545
   PubMed Web of Science ®Google Scholar
• Keryer G, Witczak O, Delouvee A, Kemmner W A, Rouillard D, Tasken K, et al. Dissociating the centrosomal matrix protein AKAP450 from centrioles impairs centriole duplication and cell cycle progression. Mol Biol Cell 2003; 14: 2436–2446
   Google Scholar
• Nigg E A. Centrosome aberrations: cause or consequence of cancer progression?. Nat Rev Cancer 2002; 2: 815–825
   PubMed Web of Science ®Google Scholar
• Maxwell C A, Keats J J, Crainie M, Sun X, Yen T, Shibuya E, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003; 14: 2262–2276
   PubMed Web of Science ®Google Scholar
• Maxwell C A, Keats J J, Belch A R, Pilarski L M, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 2005; 65: 850–860
   PubMed Web of Science ®Google Scholar
• Maxwell C A, Rasmussen E, Zhan F, Keats J J, Adamia S, Strachan E, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004; 104: 1151–1158
   PubMed Web of Science ®Google Scholar
• Chng W J, Ahmann G J, Henderson K, Santana-Davila R, Greipp P R, Gertz M A, et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3669–3675
   PubMed Web of Science ®Google Scholar
• Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585–598
   PubMed Web of Science ®Google Scholar
• Berdnik D, Knoblich J A. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002; 12: 640–647
   PubMed Web of Science ®Google Scholar
• Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003; 278: 51786–51795
   PubMed Web of Science ®Google Scholar
• Glover D M, Leibowitz M H, McLean D A, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81: 95–105
   PubMed Web of Science ®Google Scholar
• Marumoto T, Zhang D, Saya H. Aurora-A – a guardian of poles. Nat Rev Cancer 2005; 5: 42–50
   PubMed Web of Science ®Google Scholar
• Anand S, Penrhyn-Lowe S, Venkitaraman A R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51–62
   PubMed Web of Science ®Google Scholar
• Dutertre S, Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol Interv 2003; 3: 127–130
   Google Scholar
• Buschhorn H M, Klein R R, Chambers S M, Hardy M C, Green S, Bearss D, et al. Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 2005; 64: 341–346
   PubMed Web of Science ®Google Scholar
• Tatsuka M, Sato S, Kitajima S, Suto S, Kawai H, Miyauchi M, et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005; 24: 1122–1127
   PubMed Web of Science ®Google Scholar
• Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899–2905
   PubMed Web of Science ®Google Scholar
• Harrington E A, Bebbington D, Moore J, Rasmussen R K, Ajose-Adeogun A O, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262–267
   PubMed Web of Science ®Google Scholar
• Warner S L, Bashyam S, Vankayalapati H, Bearss D J, Han H, Von Hoff D D, et al. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 2006; 5: 1764–1773
   PubMed Web of Science ®Google Scholar
• Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006; 12: 4080–4089
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927–936
   PubMed Web of Science ®Google Scholar
• Gizatullin F, Yao Y, Kung V, Harding M W, Loda M, Shapiro G I. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668–7677
   PubMed Web of Science ®Google Scholar
• Giles F J, Cortes J E, Jones D, Bergstrom D A, Kantarjian H M, Freedman S J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109:500 – 502
   Google Scholar
• Shi Y, Reiman T, Li W, Maxwell C A, Sen S, Pilarski L, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007; 109: 3915–3921
   PubMed Web of Science ®Google Scholar
• Damiano J S, Cress A E, Hazlehurst L A, Shtil A A, Dalton W S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667
   PubMed Web of Science ®Google Scholar
• Pugacheva E N, Golemis E A. The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat Cell Biol 2005; 7: 937–946
   PubMed Web of Science ®Google Scholar